

Article

Perceptions of and Preparedness for the Application of Pharmacoeconomics in Practice, among Final Year Bachelor of Pharmacy Students in South Africa: A National Cross-Sectional Study

Carlien Schmidt ¹, Moliehi Matlala ^{1,*}, Brian Godman ^{1,2,3}, Amanj Kurdi ^{1,2,4} and Johanna C. Meyer ¹

¹ Department of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Molotlegi Street, Garankuwa, Pretoria 0208, South Africa

² Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK

³ Centre of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman 346, United Arab Emirates

⁴ Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil 44001, Iraq

* Correspondence: moliehi.matlala@smu.ac.za

Citation: Schmidt, C.; Matlala, M.; Godman, B.; Kurdi, A.; Meyer, J.C. Perceptions of and Preparedness for the Application of Pharmacoeconomics in Practice, among Final Year Bachelor of Pharmacy Students in South Africa: A National Cross-Sectional Study. *Pharmacy* **2023**, *11*, 54. <https://doi.org/10.3390/pharmacy11020054>

Academic Editors: Jon Schommer, Brian J. Piper and Sue Jordan

Received: 26 October 2022

Revised: 10 March 2023

Accepted: 11 March 2023

Published: 14 March 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: For the improvement of access to health, many countries including South Africa, have adopted universal healthcare. However, this requires skills to apply health technology assessments for the facilitation of investment decisions. This study aimed to ascertain final year Bachelor of Pharmacy (BPharm) students' perceptions of the relevance of pharmacoeconomics in pharmacy practice, and their level of preparedness to apply pharmacoeconomic principles, using a quantitative, cross-sectional, and descriptive design. Data were collected using a self-administered questionnaire over 12 months, and included student demographics, knowledge about pharmacoeconomics and its applicability in practice, as well as students' satisfaction with the appropriateness of the curriculum content. Five of nine universities offering pharmacy education took part. The overall student response rate was 38.1% (189/496), with 26.2% (45/172) of students signifying a good understanding of basic pharmacoeconomic concepts. Pharmacoeconomics application in South Africa was perceived to be relevant by 87.5% (140/160); however, 47.0% (79/168) felt they were not prepared to apply pharmacoeconomic principles in medicine management, and 86.7% (137/158) wanted to acquire additional pharmacoeconomic knowledge. Whilst students' perceptions of the relevance of pharmacoeconomics were positive, results indicated a gap in knowledge, understanding, and application. Addressing this gap may increase students' preparedness to apply pharmacoeconomic principles and better equip them for the practical application of pharmacoeconomics post qualification. Consequently, we have started this process.

Keywords: pharmacoeconomics; universal health coverage; BPharm final year students; cost effectiveness; South Africa

1. Introduction

Pharmaceutical therapy-related expenditure has become an essential consideration to healthcare payers worldwide focusing on pharmacoeconomic analyses, with medicine expenditure in some low- and middle-income countries (LMICs) accounting for up to 70% of total healthcare expenditure [1–5]. In high-income countries, there is an increasing focus on new medicines for cancer and orphan diseases as requested prices increase with often limited health gain coupled with the potential to overwhelm universal healthcare systems with growing expenditures [6–8]. These concerns have intensified the focus on

the necessity for the scientific valuation of costs and consequences of pharmaceutical treatments, including vaccines to guide future investments and policy decisions [1,9]. Limited healthcare resources have also increased interest in assessing the value and feasibility of funding competing healthcare treatments and programmes by performing pharmacoeconomic evaluations, especially among LMICs [3,10–14]. The rise in pharmacoeconomic research application is expanding the need for qualified individuals, who are able to analyse and understand research findings and translate these into practice, especially among LMICs with resource and other concerns [3,10,15–21].

To date, South Africa has utilised dedicated methods in specific situations during reimbursement and pricing decision-making process for medicines rather than a broader use in priority setting, where there are competing demands across disease areas [9,22,23]. Pharmacoeconomic submissions to the South African National Department of Health (NDoH) Pricing Committee have taken place voluntarily and for selected medicines in the private health sector [22–24]. This is due to the fact that South Africa currently has an unequal two-tier healthcare system, with a public and private sector. The public sector, which is state funded caters for approximately 80% of the population with the goal of universal healthcare (UHC) [25,26]. The private sector, which caters for approximately 20% of the population, is largely funded through medical aid contributions or health insurance [27]. Consequently, medicines in the public sector are usually subject to tenders as they have typically lost their patents. [23,28]. This is not the case for possible new medicines in the private sector, with pharmacoeconomic guidelines in South Africa initially developed for the private sector, recommending a third-party payer perspective [22]. Nonetheless, pharmacoeconomic analyses are now emerging in the public sector to help appraising different treatment approaches, including different public health approaches, with competing demands for finite resources [29–37]. This inconsistent use of pharmacoeconomic submissions may imply that national pharmacoeconomic evaluations and education settings are still emerging, although there are moves to improve submissions through international comparisons [10,23,38]. In this regard, South Africa will soon follow in the footsteps of many international countries concerning pharmacoeconomic research application when the National Health Insurance (NHI) system, aimed at universal health coverage, is fully functional [25,26,38]. In the near future, it is believed that health technology assessment methodologies will be used to prioritise interventions in key areas, including health promotion, disease prevention and treatment, with the most cost-effective, evidence-based therapies and strategies being deployed and paid for under the NHI [25]. This is similar to situations in other LMICs [11–14]. We will continue to thoroughly monitor the situation with its implications for the necessity to increase pharmacoeconomic understanding among healthcare students, with the likeliness of strengthening the pharmacoeconomic guidelines in South Africa.

With their knowledge of medicines and their costs, pharmacists are uniquely equipped to use pharmacoeconomic analyses to influence expenditure on medicines and the distribution of resources for medicines [1,3,15,23,25,26]. This builds on previous approaches, including ABC- and VEN-analyses of medicine use and expenditures in hospitals [15,39–41]. The South African National Drug Policy covers various activities contributing to effective medicines management. Within this policy, the pharmacist's role is to ensure that the South African population receives the medicines they need at a cost that is affordable to them, and the healthcare system, is also clearly stipulated [24]. This role further enhances the need for appropriate pharmacoeconomic knowledge and skills among pharmacists going forward.

The number of academic institutions providing education on pharmacoeconomic analyses has grown internationally over the past two decades, with many institutions also increasing the extent of health economics coursework amongst undergraduate pharmacy students [3,16–20]. Similarly, education on pharmacoeconomics is now incorporated into the South African Bachelor of Pharmacy (BPharm) programmes, complying with the South African Pharmacy Council's exit level outcomes for entry-level pharmacists and the

qualification standards of the South African Qualifications Authority [21,42]. The education of pharmacoeconomic principles in South Africa was briefly covered in a study published in 2005 [3]. While this study mentioned a requirement for increased education on pharmacoeconomics in developing countries, the individual perceptions of undergraduate pharmacy students in South Africa regarding pharmacoeconomics have yet to be robustly investigated [3]. A South African-based study focusing on pharmacoeconomics in the healthcare system in Gauteng province highlighted that pharmacoeconomics education is essential for increased awareness and understanding of the subject among healthcare decision-makers, with most respondents concurring that pharmacoeconomics education would aid them in their scope of practice [43]. However, this has not been considered further.

A shortfall in healthcare professionals' and students' knowledge and understanding of pharmacoeconomics, and its application in medicines management, appears to be universal across countries, including LMICs [16,44–46]. The results of a South African study conducted in 2005 highlighted a lack of pharmacoeconomic knowledge among healthcare workers, epidemiologists, and trained staff, subsequently leading to an absence of measures to control resources in both the public and private healthcare sectors [43]. This is starting to be addressed in South Africa and other African countries with groups, such as HTAi having dedicated interest groups for developing countries (<https://htai.org/htai-in-developing-countries/>; accessed on 24 November 2022) as well as ISPOR with its African chapter (<https://www.ispor.org/member-groups/global-groups/networks/africa-network/executive-committee>; accessed on 24 November 2022). Applied pharmacoeconomics is often viewed as an important skill set for pharmacists internationally, and is acknowledged for improving health system performance across countries [3,43,45,47,48]. Despite this positive view on the role of pharmacoeconomics in maximising patients' outcomes from the available healthcare resources, healthcare students and decision-makers commonly feel unprepared to apply pharmacoeconomic principles in practice [16,45,48]. Researchers universally suggest increased education regarding pharmacoeconomics during undergraduate and postgraduate health education programmes to address current gaps in knowledge and the application of pharmacoeconomic analyses [3,10,16,17,43,44,47].

The expected future use of pharmacoeconomic evidence in South Africa as part of the government's NHI plan clearly indicates that pharmacists will increasingly need knowledge, skills, and capabilities for critical analyses and implementation of pharmacoeconomic research findings. One way to support this is through adequate education in this field among BPharm students in South Africa [3,16,20]. Consequently, this study was undertaken to determine final year BPharm students' perceptions of the relevance of pharmacoeconomics in their future practice in South Africa and their level of preparedness to apply their knowledge in practice, and be able to undertake and critically review pharmacoeconomic studies in the future.

2. Materials and Methods

2.1. Study Design and Population

This was a descriptive cross-sectional study among final-year BPharm students enrolled at the nine South African universities offering the BPharm programme. Therefore, all nine universities were invited to allow their final year BPharm students to participate in the study. Specific inclusion criteria for students were: (i) Final year students enrolled in a BPharm programme at a South African university; and (ii) students willing to participate in the study.

2.2. Data Collection Instrument and Procedure

Data were collected through a structured, self-administered questionnaire available in English. The questionnaire content was based on a comprehensive review of literature sources, the current pharmacoeconomic curricular content for the South African BPharm programme, and pharmacoeconomic theoretical principles [3,16,17,19,42,44,45,47,49–51]. Three pharmacoeconomic experts initially reviewed the questionnaire, with their feedback subsequently incorporated into the revised questionnaire.

A pre-test of the questionnaire was conducted among six pharmacist interns at the SMU School of Pharmacy to determine its face validity, length of completion, and relevance of the questions included.

The final questionnaire consisted of 31 questions (Supplementary File S1), grouped into six sections to collect students' demographic information, evaluate exposure to training on pharmacoeconomic principles and techniques during BPharm enrolment, and assess perceptions and preparedness pertaining to pharmacoeconomic analyses using a five-point Likert scale [44,45]. A Likert scale was considered the most appropriate measurement scale to assess respondents' perceptions and preparedness, as it allows for the measurement of different levels of agreement and disagreement. As a result, providing good insights into respondents' perceptions. Furthermore, the Likert scale has been used extensively in descriptive and quantitative studies across countries [52–54].

Students completed a paper-based version of the questionnaire, with completed questionnaires returned to the first author in a sealed envelope, or completed the questionnaire electronically using SurveyMonkey®, an online survey platform. Data were collected between November 2018 and December 2019, varying among universities with an average of 3 months per university.

2.3. Data Capture and Analysis

Prior to analysis, participating universities were anonymised and recoded as "A", "B", "C", "D", and "E". Captured data were proofread, cross-checked, and discrepancies resolved. Data analysis was descriptive and undertaken in custom formulated Microsoft Office Excel® spreadsheets. Categorical variables were summarised by frequency counts and percentages.

Responses to the five-point Likert scale questions were condensed into three categories to facilitate the analysis and interpretation of results. Responses to open-ended questions were typed, categories were manually created, and responses were coded into these categories and counted where applicable.

Even though comparing the individual universities was not the primary aim of this study, a sensitivity analysis was conducted to assess the effect of variation in response rates amongst the universities on the study outcomes. For this purpose, we grouped universities based on their response rates into "Low-", "Medium-", and "High-" response rates. Subsequently, we compared the scores for two randomly selected study outcomes, namely "Level of understanding of pharmacoeconomics" and "Preparedness to apply pharmacoeconomics in practice" between the three groups, using one-way ANOVA and Fisher Exact tests, respectively. Herein, p -values < 0.05 were considered as statistically significant.

2.4. Ethical Considerations

The Sefako Makgatho University Research Ethics Committee provided ethics clearance for the study (SMUREC/P/97/2018:PG), after which the nine universities were invited to participate in the study. Upon acceptance of the invitation by a university, permission to conduct the study was formally requested, which included submission of the protocol to the respective university's research ethics committees. Only upon receipt of permission and ethics clearance from a particular university students were invited to participate in the survey. Participation was voluntary, responses were anonymous, and no personal,

identifying information was collected. Students participating in the survey first provided informed consent before completing the questionnaire. Data were treated as highly confidential, with completed questionnaires stored under secure conditions. All data are stored securely for future reference and for a period of 5 years, after which it will be destroyed according to university policies.

3. Results

3.1. Response Rate

Eight of the nine invited universities offering the BPharm programme in South Africa responded positively to the invitation. Five of the eight universities were able to provide ethics clearance for their students to participate in the study during the allocated study period. The ethical clearance process at two of the three remaining universities was delayed considerably, with permission granted only after data collection for the study had been concluded. No further response was received from the one remaining university.

The final target study population from the five universities included 496 final year BPharm students, from which an overall response rate of 38.1% (189/496) was obtained, ranging from 18.1% to 93.9% at individual universities (Table 1). Four of the universities' students responded using the paper-based version of the questionnaire, while the students at one of the universities responded using the electronic platform (Table 1). Overall, 48.1% (91/189) of students answered all questions in the questionnaire. As a result of inconsistent responses, sample sizes varied between questions. Twenty-two of the 189 students (11.6%) provided additional comments on pharmacoeconomics.

Table 1. Response rate per university.

University	Number of Final Year Bachelor of Pharmacy Students, 2018	Response Rate	
		Number (<i>n</i>)	Percentage (%)
A	80	44	55.0
B	94	17	18.1
C	141	58	41.1
D	49	46	93.9
E	132	24	18.2
Total	496	189	38.1

Keys: A, C, D, E = Universities where students responded through paper-based questionnaires; B = University where students responded through online questionnaires; A–D = Universities from which data were collected in 2018; the number of final year Bachelor of Pharmacy students are given for 2018; Source: South African Pharmacy Council (SAPC), 16 February 2018; E = University from which data were collected in 2019; the number of final year Bachelor of Pharmacy students are given for 2019.

3.2. Respondent Demographics

Table 2 demonstrates that the mean age of students was 24.3 years ($SD = 2.34$), ranging between 20.0 and 32.9 years, with the majority being female (71.4%). A few students (7.1%; 13/184) held other degrees. Nearly half of the students surveyed (49.2%) intended to complete their internships at public sector institutional pharmacies.

Table 2. Respondent demographics.

Student Demographics		Number (%)
Gender (<i>n</i> = 189)	Female	135 (71.4)
	Male	54 (28.6)
Race (<i>n</i> = 187)	Black African	140 (74.9)
	Coloured	7 (3.7)
	Indian	16 (8.6)
	White	24 (12.8)
Age (<i>n</i> = 182)	Younger than 22 years	12 (6.6)
	22–25 years	126 (69.2)
	Older than 25 years	44 (24.2)
Degrees other than BPharm (<i>n</i> = 13)	Master of Medicine in Physiology	1 (7.7)
	Bachelor of Science	2 (15.4)
	Bachelor of Science (Honours) in Cellular Biology	1 (7.7)
	Bachelor of Science (Honours) in Microbiology	1 (7.7)
	Bachelor of Science in Biochemistry	1 (7.7)
	Bachelor of Science in Biochemistry and Physiology	1 (7.7)
	Bachelor of Science in Biological Science	1 (7.7)
	Bachelor of Science in Medicinal Science	1 (7.7)
	Bachelor of Science in Microbiology and Biochemistry	1 (7.7)
Bachelor of Science in Molecular Life Sciences	3 (23.1)	
Intended sector of internship (<i>n</i> = 179)	Academic institution	19 (10.6)
	Community pharmacy	27 (15.1)
	Manufacturing pharmacy	10 (5.6)
	Private sector institutional pharmacy	14 (7.8)
	Public sector institutional pharmacy	88 (49.2)
	The respondent did not know	21 (11.7)

3.3. Pharmacoeconomics Education during the BPharm Programme

Overall, 37.8% (*n* = 62) of BPharm students in this study indicated that pharmacoeconomics was covered under “Hospital Pharmacy Practice”-related subjects (Table 3). Of the 178 students, 74 (41.6%) indicated that pharmacoeconomics was presented during their fourth year of the programme. The majority of students (87.3%; 151/173) underwent a formal assessment of their knowledge of pharmacoeconomics during their BPharm programme. Table 3 shows that most students (88.0%) recalled being taught pharmacoeconomics through lectures. The number of hours allocated to pharmacoeconomics in students’ timetables ranged from 0.1 to 40 h (mean = 4.4; SD = 4.52). Of the 22 additional comments at the end of the survey, five students (22.7%) said that “pharmacoeconomics should be a subject/module/course on its own.”

Table 3. Pharmacoeconomics education during the Bachelor of Pharmacy programme.

Pharmacoeconomics Education	Number (%)
Subject/module/course under which pharmacoeconomics was offered (<i>n</i> = 164) *	
Community Pharmacy-Based Learning Community Pharmacy Practice Community Pharmacy	10 (6.1)
Hospital Community Pharmacy Hospital Pharmacy and Community Pharmacy Hospital Pharmacy Practice and Community Pharmacy Practice	4 (2.4)
Hospital Management Hospital Pharmacy Hospital Pharmacy Management Hospital Pharmacy Practice Hospital Pharmacy Practice-Based Learning Hospital-Based Learning Module Hospital-Based Pharmacy	62 (37.8)
Natural Products and Evidence	1 (0.6)

Pharmaceutical Care	1 (0.6)
Pharmaceutical Logistics, Economics and Management Pharmaceutical Logistics Pharmaceutical Management	51 (31.1)
Pharmacology	2 (1.2)
Pharmacy and the Professional Environment Pharmacy Practice and the Professional Environment Pharmacy Practice Philosophy of Pharmacy Practice	19 (11.6)
Pharmacy People and Systems	8 (4.9)
Pharmacy Research Project Pharmacy Research Research Methodology Research Module	6 (3.7)
Specialised Pharmacy and Pharmacoeconomics Specialised Pharmacy	3 (1.2)
Third Year level	68 (38.2)
Fourth Year level	74 (41.6)
Both third and fourth-year levels	36 (20.2)
Elective subject/module/course	4 (2.3)
Mandatory subject/module/course	158 (89.3)
Inclusion of pharmacoeconomics other than mandatory or elective subject/module/course	2 (1.1)
The respondent did not know	13 (7.3)
Forms of pharmacoeconomics knowledge assessment during BPharm programme (n = 128) *	
Assignments	15 (11.7)
Calculations	4 (3.1)
Exams	81 (63.3)
Multiple choice questions	5 (3.9)
Oral exam	5 (3.9)
Portfolios	1 (0.8)
Practical work Experimental learning PTC-meeting attendance Taking part in analyses	4 (3.1)
Presentations	3 (2.3)
Scenario-based questions Case studies Application questions In-depth questions	6 (4.7)
Summative and formative assessments Assessments Final assessments Module assessments	8 (6.3)
Tests (Semester tests Class tests)	70 (54.7)
Workshops	1 (0.8)
Medium of pharmacoeconomics teaching during BPharm programme (n = 175) *	
Lectures	154 (88.0)
Practical work	45 (25.7)
Tutorials	37 (21.1)
Workshops	45 (25.7)
Another medium of teaching pharmacoeconomics	4 (2.3)
Hours of pharmacoeconomics training received during BPharm programme (n = 100)	
Less than 1 h	20 (20.0)
1–4 h	46 (46.0)
5–7 h	14 (14.0)
More than 7 h	20 (20.0)

* Respondents were allowed more than one answer to the question; PTC: Pharmaceutical and Therapeutics Committee.

3.4. Understanding of Pharmacoeconomic Concepts

Table 4 demonstrates that, of the 172 students indicating their level of understanding of pharmacoeconomic concepts, 40 (23.3%) signified an overall poor understanding of these concepts, whereas 83 (48.3%) had a fair understanding. Only over a quarter of students signified an overall good understanding (45/172), and 66.2% were able to correctly answer questions regarding the scope of pharmacoeconomics (104/157). However, 37.0% of students (57/154) wrongly indicated that “pharmacoeconomics calculates the costs of medicines and treatments only”. Only 23.4% of students (33/138) provided correct

answers to each type of analysis, namely, cost-minimization analysis, cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis.

Table 4. Understanding of pharmacoeconomic concepts and their application by South African final year Bachelor of Pharmacy students.

Understanding of Pharmacoeconomic Concepts and Their Application		Number (%)			
		Poor	Fair	Good	NA
Level of understanding	Basic pharmacoeconomic concepts (<i>n</i> = 172)	26 (14.9)	92 (53.6)	51 (29.7)	3 (1.8)
	Advanced pharmacoeconomic concepts (<i>n</i> = 172)	53 (30.8)	74 (43.0)	40 (23.8)	5 (2.9)
Correct answer					
What the scope of pharmacoeconomics entails	Evaluates and measures costs and benefits of drug therapy (<i>n</i> = 162)				154 (95.1)
	Involves a combination of health economics and clinical outcomes (<i>n</i> = 156)				145 (92.9)
	Compares different pharmaceutical interventions to each other (<i>n</i> = 154)				125 (81.2)
	Examines and calculates costs of medicines and treatments only (<i>n</i> = 154)				89 (57.8)
	Measures the impact of medicine-related costs on medicine budgets (<i>n</i> = 156)				5 (3.2)
Correct answer					
How outcomes for pharmacoeconomic analyses are measured	CBA outcomes may be similar or different units and always expressed in monetary units (<i>n</i> = 139)				28 (20.1)
	CEA outcomes are measured in similar natural health units across therapies (<i>n</i> = 139)				30 (21.6)
	CMA outcomes are measured by assuming that health benefits are equivalent and can take any form (<i>n</i> = 138)				26 (18.8)
	CUA outcomes value health benefits across therapies in similar units, depending on individual preference (<i>n</i> = 136)				45 (33.1)

NA: Not applicable; CBA: Cost-benefit analysis; CEA: Cost-effectiveness analysis; CMA: Cost-minimisation analysis; CUA: Cost-utility analysis.

3.5. Relevance of Pharmacoeconomics in Practice

Overall, the majority of students (87.5%; 140/160) perceived the application of pharmacoeconomics in South African medicines management as “relevant” (Table 5). Of the 22 additional comments, most students (88.8%) felt that applying pharmacoeconomics in practice was an essential skill that pharmacists should possess, with 84.0% indicating that pharmacists should be responsible for performing pharmacoeconomic evaluations in practice.

Table 5. Perceptions of final year Bachelor of Pharmacy students regarding the relevance of pharmacoeconomics in South African medicines management.

The relevance of pharmacoeconomics in South African medicines management	Number (%)				
	Irrelevant		Neutral No opinion	Relevant	
	Strongly disagree	Disagree		Agree	Strongly agree
Improves medicine-related decisions in South African healthcare system [<i>n</i> = 159]	7 (4.4)		8 (5.0)	144 (90.6)	
	5 (3.1)	2 (1.3)		69 (43.4)	75 (47.2)
Ensures optimal use of medicine budgets across the South African public health sector [<i>n</i> = 159]	11 (6.9)		6 (3.8)	142 (89.3)	
	7 (4.4)	4 (2.5)		79 (49.7)	63 (39.6)
Should form an integral part of the South African National Health Insurance system [<i>n</i> = 159]	9 (5.7)		12 (7.5)	138 (86.8)	
	6 (3.8)	3 (1.9)		67 (42.1)	71 (44.7)
Will improve access to medicines [<i>n</i> = 160]	7 (4.4)		17 (10.6)	136 (85.0)	
	5 (3.1)	2 (1.3)		83 (51.9)	53 (33.1)
Instances of pharmacoeconomic analyses application in South Africa	Not used		Neutral No opinion	Used	
	Strongly disagree	Disagree		Agree	Strongly agree
	Pricing of medicines [<i>n</i> = 158]	8 (5.1)		14 (8.9)	136 (86.1)
	3 (1.9)	5 (3.2)		89 (56.3)	47 (29.7)
Planning of production and sales of medicines [<i>n</i> = 158]	8 (5.1)		16 (10.1)	134 (84.8)	
	4 (2.5)	4 (2.5)		100 (63.3)	34 (21.5)
Inclusion of medicines in medicine formularies (e.g., EML, medical aid formularies, STGs) [<i>n</i> = 158]	11 (7.0)		25 (15.8)	122 (77.2)	
	6 (3.8)	9 (5.7)		70 (44.3)	52 (32.9)
Clinical decision-making at the individual patient level, in the case of medicine not included in EML, medical aid formularies, STGs [<i>n</i> = 158]	12 (7.6)		29 (18.4)	117 (74.1)	
	4 (2.5)	8 (5.1)		70 (44.3)	47 (29.7)
Registration of new medicines with the South African Health Products Regulatory Authority [<i>n</i> = 158]	15 (9.5)		30 (19.0)	113 (71.5)	
	6 (3.8)	5 (3.2)		75 (47.5)	38 (24.1)
	Not important		Neutral No opinion	Important	
	Strongly disagree	Disagree		Agree	Strongly agree
Pharmacoeconomics is an important skill that South African pharmacists should possess [<i>n</i> = 160]	7 (4.4)		11 (6.9)	142 (88.8)	
	6 (3.8)	1 (0.6)		69 (43.1)	73 (45.6)
	Number (%)				
South African health sector to which pharmacoeconomic application is relevant [<i>n</i> = 159]	The private sector only (e.g., medical aid formularies)			6 (3.8)	
	Public sector only (e.g., EML, STGs)			11 (6.9)	
	Both private and public sector			134 (84.3)	
	The respondent did not know			8 (5.0)	
Professions to perform pharmacoeconomic analyses in practice [<i>n</i> = 163]	Health economists			140 (85.9)	
	Pharmacists			137 (84.0)	
	Medical practitioners			71 (43.6)	
	Economists			64 (39.3)	
	Accountants			52 (31.9)	
	Nursing practitioners			42 (25.8)	
	Epidemiologists			33 (20.2)	
	Mathematical modellers			20 (12.3)	
	Demographers			16 (9.8)	
	People with mathematical background			15 (9.2)	

EML: Essential medicines list; STGs: Standard treatment guidelines.

3.6. Preparedness for Application of Pharmacoeconomics in Practice

Only over a third of students (38.1%; 64/168) felt that their undergraduate exposure to pharmacoeconomics was insufficient to understand basic principles (Table 6). Nearly half of the students (54.2%; 91/168) perceived pharmacoeconomics as “interesting” and “enjoyable”, with 47.0% (79/168) who felt not adequately prepared to apply pharmacoeconomics in practice. Less than half (45.7%; 75/164) of the students thought of themselves as competent to perform basic pharmacoeconomic analyses.

Table 6. Preparedness of South African final year Bachelor of Pharmacy students for application of pharmacoeconomics in medicines management.

Opinions on pharmacoeconomics		Number (%)				
		Negative		Neutral No Opinion	Positive	
		Strongly Disagree	Disagree		Agree	Strongly Agree
Exposure to pharmacoeconomics during the BPharm programme was sufficient to understand basic principles and concepts [<i>n</i> = 168]		64 (38.1)		13 (7.7)	91 (54.2)	
Pharmacoeconomics is interesting and enjoyable [<i>n</i> = 168]		40 (23.8)		37 (22.0)	91 (54.2)	
		11 (6.5)	29 (17.3)		65 (38.7)	26 (15.5)
Preparedness to apply pharmacoeconomics in practice		Unprepared		Neutral No opinion	Prepared	
		Strongly disagree	Disagree		Agree	Strongly agree
Knows where to find more information on pharmacoeconomic concepts [<i>n</i> = 168]		48 (28.6)		25 (14.9)	95 (56.5)	
Can interpret results of pharmacoeconomic analyses for decision-making [<i>n</i> = 165]		59 (35.8)		29 (17.6)	77 (46.7)	
Adequately prepared to apply pharmacoeconomic concepts in practice to conduct analyses [<i>n</i> = 168]		79 (47.0)		31 (18.5)	58 (34.5)	
		15 (8.9)	64 (38.1)		50 (29.7)	8 (4.8)
		Negative		Neutral No opinion	Positive	
		Very incompetent	Incompetent		Competent	Very compe- tent
Competence in performing basic pharmacoeconomic analyses [<i>n</i> = 164]		45 (27.4)		44 (26.5)	75 (45.7)	
		10 (6.1)	35 (21.5)		68 (41.7)	7 (4.3)
		Never		Rarely	Often	
Expected frequency of performing pharmacoeconomic analyses	Cost-minimisation analysis [<i>n</i> = 164]	23 (14.0)		62 (37.8)	79 (48.2)	
	Cost-benefit analysis [<i>n</i> = 161]	19 (11.8)		64 (39.8)	78 (48.4)	
	Cost-effectiveness analysis [<i>n</i> = 163]	21 (12.9)		72 (44.2)	70 (42.9)	
	Cost-utility analysis [<i>n</i> = 163]	24 (14.7)		74 (45.4)	65 (39.9)	

3.7. Sensitivity Analysis

Based on the universities’ response rates (see Table 1), Universities A and C were grouped into “Low response rate”, Universities B and E into “Medium response rate”, and University D labelled as “High response rate”. The mean scores for understanding of basic pharmacoeconomic concepts ($p = 0.006$) and advanced pharmacoeconomic concepts ($p < 0.001$) were statistically significantly different between the three groups (see Table 7). However, post-hoc analysis showed no significant difference between the high- and low-response rate groups for basic ($p = 0.991$) and advanced ($p = 0.774$) understanding of pharmacoeconomic analyses. In terms of “Preparedness to apply pharmacoeconomics in practice,” there was no statistically significant difference between the three groups for both being able to interpret the results of pharmacoeconomic analyses for decision-making ($p = 0.810$) and being adequately prepared to apply pharmacoeconomic concepts in practice to conduct the analyses ($p = 0.792$) (see Table 8).

Table 7. Mean level of understanding of pharmacoeconomic concepts distributed by university response rate.

Level of Understanding of Pharmacoeconomics		University D	Universities B and E	Universities A and C
		High Response Rate	Medium Response Rate	Low Response Rate
<i>n</i>		45	95	31
Basic pharmacoeconomic concepts	Mean (SD)	2.316 (0.5697)	2.036 (0.6123)	2.332 (0.4423)
	<i>p</i> -value *	0.006		
Advanced pharmacoeconomic concepts	Mean (SD)	2.271 (0.4251)	1.796 (0.6135)	2.184 (0.4872)
	<i>p</i> -value *	<0.001		

* One-way ANOVA.

Table 8. Preparedness for the application of pharmacoeconomics in practice distributed by university response rate.

Preparedness to Apply Pharmacoeconomics in Practice		University D	Universities B and E	Universities A and C
		High Response Rate	Medium Response Rate	Low Response Rate
<i>n</i>		44	93	28
Can interpret results of pharmacoeconomic analyses for decision-making	Agree; No (%)	22 (50.0)	40 (43.0)	15 (53.6)
	Neutral; No (%)	19 (43.2)	44 (47.3)	12 (42.9)
	Disagree; No (%)	3 (6.8)	9 (9.7)	1 (3.6)
	<i>p</i> -value *	0.810		
<i>n</i>		46	94	28
Adequately prepared to apply pharmacoeconomic concepts in practice to conduct analyses	Agree; No (%)	17 (37.0)	31 (33.0)	10 (35.7)
	Neutral; No (%)	26 (56.5)	55 (58.5)	14 (50.0)
	Disagree; No (%)	3 (6.5)	8 (8.5)	4 (14.3)
	<i>p</i> -value *	0.792		

* Fisher Exact.

3.8. Future Education in Pharmacoeconomics

The vast majority of students (93.8%; 152/162) believed that future education regarding pharmacoeconomic studies and their application was essential to their role as pharmacists, while only five (3.1%) perceived further education as “not necessary”. Similarly, most surveyed students (84.4%; 135/160) would have wanted more education on pharmacoeconomics during their BPharm training. Among the additional comments provided, 27.2% (6/22) of the students thought that undergraduate pharmacoeconomics tuition should be increased.

The majority of students (86.7%; 137/158) wanted to acquire further pharmacoeconomics knowledge, of whom two thirds (66.4%; 91/137) wanted to acquire further knowledge through continuous professional development (CPD) programmes, 36 (26.3%) through self-study, and 40 (29.2%) through postgraduate studies. Among the 22 additional comments at the end of the survey, three students (13.6%) indicated that they would like to acquire more knowledge regarding pharmacoeconomics.

4. Discussion

The overall response rate of 38.1% is seen as acceptable for voluntary questionnaire surveys, and similar to other published studies in this area [44,45,47,55,56].

The study results principally highlighted two key issues for the future, which are the most important outcomes of this study. First, few pharmacy students had an overall good understanding of pharmacoeconomic concepts. However, only over half of those surveyed felt they received enough teaching exposure to pharmacoeconomics to understand the basic principles and concepts during their university training. However, the majority wanted to receive more undergraduate training and tuition. Second, less than half of the

students participating in the survey felt competent to perform basic pharmacoeconomic analyses, with more students considering themselves as “not prepared” to conduct these studies compared with those who feel prepared.

Most students in our study underwent education regarding pharmacoeconomics in their fourth (final) year. This is consistent with the study by Catić and Skrbo in Bosnia, in which most pharmacy students were taught pharmacoeconomics in their fifth (final) year [16]. We assume that students nearing the end of their BPharm studies have the necessary fundamental medicine-related knowledge to fully understand pharmacoeconomics and its application. However, this is not always the case.

According to most students in this study, pharmacoeconomics was a mandatory subject/module/course, which concurs with the findings from similar studies [3,16,19,20,57–60]. However, the mean hours spent teaching pharmacoeconomics in South Africa varied significantly compared with similar studies outside of South Africa [3,17,19,47,50]. This might help in explaining why more than a third of students in our study felt they did not receive sufficient undergraduate exposure to pharmacoeconomics and its principles. This may have adversely affected their understanding of pharmacoeconomic concepts, competence to perform basic analyses, and preparedness to conduct pharmacoeconomic analyses in practice, which urgently needs to be addressed [61].

Encouragingly, few students in our study had an overall poor understanding of pharmacoeconomic concepts or principles. This compares with other studies, where most respondents found these concepts unclear or difficult to understand or indicated that they were “not very familiar” or “slightly familiar” with these concepts [16,46,49,61]. At the same time, the number of students in our study with an overall good understanding of pharmacoeconomic concepts and their application in medicines management was similar to other studies [44,45,47,49]. When questioned about the scope of pharmacoeconomic analyses, more students in our study knew the correct answer to the question, compared with 39.0% of students in the study by Catić and Skrbo [16]. However, more students in our study incorrectly indicated that “pharmacoeconomics examines and calculates the costs of medicines and treatments only” compared with only 13.0% of the respondents recorded in the study by Catić and Skrbo [16].

Of concern, many students in our study incorrectly indicated that budget impact analysis formed part of the scope of pharmacoeconomics, while not being considered as a pharmacoeconomic analysis sub-type in reality. This is an issue to address as budget impact analyses are increasingly important in LMICs when assessing the possible role and value of new medicines [62–65]. This is balanced against the finding that the number of students correctly indicating that pharmacoeconomic studies compare different therapeutic interventions was appreciably higher than only 7.0% of students reported by Catić and Skrbo [16]. In general, more students in our study had a good knowledge of the scope of pharmacoeconomics compared with only 38.9% of students reported by Catić and Skrbo [16]. Nearly a quarter of students in our survey were also able to provide the correct measure to each of the basic pharmacoeconomic analyses concurrent with similar studies [45,46,49]. The level of pharmacoeconomics understanding among the students in our study, especially regarding the scope of pharmacoeconomics, is an important factor to consider going forward. Any healthcare professional tasked with even the most basic pharmacoeconomic analyses would have to know what inputs and outcomes they are measuring when performing these evaluations in practice. Evidently, the level of students’ understanding of pharmacoeconomics is a fundamental cornerstone of their ability to perform pharmacoeconomic analyses successfully. Consequently, education offers a golden opportunity to improve their knowledge and understanding of pharmacoeconomics. The importance of addressing this gap in BPharm students’ knowledge and understanding is supported by earlier studies highlighting that the education of healthcare professionals regarding pharmacoeconomics contributes to the financial sustainability of healthcare systems [3,43,46,48].

Moreover, encouragingly, an appreciable portion of students in our study thought that applying pharmacoconomics was an essential skill that South African pharmacists should possess. This concurs with the findings of studies conducted amongst different student cohorts in India, Japan, and South Africa [3,43,45,49]. Pharmacists, with their unique knowledge of medicines and key aspects of it, including their acquisition costs, can effectively contribute to any conservation regarding health budgets, which is important in enhancing equal access to pharmaceutical care, especially in developing countries such as South Africa [3,15,66,67]. Consequently, it was encouraging that most students in our study agreed that the application of pharmacoconomics would benefit the South African healthcare system. This finding strongly correlates with Tahashildar et al. in India [45]. Moreover, how students thought of instances in which pharmaco-economic evaluations could be used in South Africa was congruent with the findings by Catić and Skrbo from Bosnia and those of Modiba from South Africa [16,43].

Furthermore, encouragingly, most of the surveyed students intended to complete their internship in South African public sector institutions, challenged with significant workforce shortages as well as medicine shortages, requiring pro-active ways to deal with this without seriously impeding on patient care [9,26,68,69]. This is important for the future as South Africa implements UHC with ever-increasing demands on scarce resources, starkly contrasting the findings of the study by Armstrong et al. [3,26,49,70].

Only over a third of the students in our current study felt that they needed to receive more pharmacoconomics exposure in their training. In addition, the majority of those surveyed would have wanted more pharmacoconomics training at an undergraduate level. This is similar to a 2002 European Pharmaceutical Student Association survey involving 22 European countries, where only over half of the students surveyed (56%) indicated that the level of pharmacoconomics education they received during their education was poor [3]. This needs addressing in the future, especially as only 19.0% of pharmacy students enrolled at the Lebanese American University School of Pharmacy believed that the number of hours spent preparing them to analyse pharmaco-economic research was inadequate [71].

Most healthcare professionals and postgraduate medical students participating in the study by Tahashildar et al. did not feel comfortable in conducting pharmaco-economic analyses. This was despite having undergone a formal assessment of their pharmaco-economic knowledge [45]. There were similar findings in the study by Umair Khan et al. [48]. Both studies concur with our study, where only a limited number of students surveyed felt prepared and competent to perform basic pharmaco-economic analyses in practice [45,48]. This study finding is emphasised by Kolassa, who suggested that pharmacy curricula did not adequately prepare students [72].

Our study also showed that half of the South African students wanted to obtain additional pharmacoconomics knowledge through CPD programmes post qualification. This compares to approximately three-quarters of postgraduate students surveyed in the study by Jayasree et al. [44]. More students in our study wanted to acquire further pharmacoconomics knowledge through self-study, which contrasts with 11.0% in the study by Jayasree et al. [44]. However, the small number of students in our study wanting to acquire pharmacoconomics knowledge through postgraduate studies corresponded with findings by Catić and Skrbo, but was in contrast with the 55.0% of respondents in the study by Jayasree et al., who believed that pharmacoconomics should be included in postgraduate studies [16,44].

We are aware of the limitations with this study. Firstly, four of the nine universities in the country offering the BPharm programme did not participate in the study during the study period as a number of them were unable to provide ethical approval in time. Secondly, two of the five participating universities had a lower response rate compared to the other universities. However, the overall rates are similar to other published studies in this area [44,45,47,55,56]. In this regard, a strength of this study was that it was conducted in the final semester of the BPharm study, assuming that students would have undergone

the necessary education to participate. In addition, the study' the future requirements for pharmaco-economic teaching for student pharmacists across South Africa to be able to equip them for the future. Consequently, we feel that the overall response rate from 189 pertinent students is extremely helpful, with the findings seen as robust in providing direction for the future.

Despite the above, we recognise that the variation in response rates among the universities could have introduced a non-response bias, however, based on the sensitivity analysis results (see Tables 7 and 8) it is unlikely that variation in the response rate could explain the variation in the study outcomes among the universities. The observed variation could possibly be explained by variations in the academic performance amongst the universities, such as staff to student ratio and emphasis on the teaching of pharmaco-economics, emphasising standardisation of pharmaco-economic curricula amongst universities in South Africa.

5. Conclusions

There is a recognised need to develop a pool of South African personnel who are able to conduct and evaluate pharmaco-economic analyses as South Africa moves toward UHC. Consequently, it was encouraging to see that most BPharm students surveyed perceived pharmaco-economics in South African medicines management as relevant to their future needs. In addition, a demand for further pharmaco-economics education exists among the next generation of pharmacists. South African undergraduate pharmacy students appear to correlate with their international counterparts regarding the gap in their understanding and knowledge of pharmaco-economic concepts and their preparedness for practical application, which needs addressing going forward.

Consequently, pharmaco-economics education should remain in the South African BPharm programme curriculum; however, the current content requires expansion. Addressing this gap during South African undergraduate pharmacy education should increase students' understanding of pharmaco-economic concepts and their preparedness for applying these analyses in practice post qualification to benefit the South African healthcare system. The BPharm curriculum is currently under review and we will continue to monitor it in future research projects.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/pharmacy11020054/s1>, File S1: Data collection instrument.

Author Contributions: Conceptualisation, C.S., M.M., B.G., and J.C.M.; methodology, M.M., B.G., A.K., and J.C.M.; validation, C.S. and M.M.; formal analysis, C.S., M.M., A.K., and J.C.M.; investigation, C.S., M.M., and J.C.M.; resources, M.M. and J.C.M.; data curation, C.S., M.M., B.G., A.K., and J.C.M.; writing—original draft preparation, C.S., M.M., and J.C.M.; writing—review and editing, C.S., M.M., B.G., A.K., and J.C.M.; supervision, J.C.M. and M.M.; project administration, M.M. and J.C.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The research received ethical approval from Sefako Makgatho Health Sciences University (SMUREC/P/97/2018: PG) and from all five universities whose students participated in the study, prior to commencement of data collection.

Informed Consent Statement: All participants signed a consent form prior to participation in the study.

Data Availability Statement: Additional data are available upon reasonable request from the corresponding author.

Acknowledgments: The authors thank the staff at all participating universities for their support in facilitating the data collection process and the final year Bachelor of Pharmacy students at the respective universities for taking the time to complete the questionnaire.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bootman, J.; Townsend, R.; McGhan, W. Introduction to Pharmacoeconomics. In *Principles of Pharmacoeconomics*, 3rd ed.; Harvey Whitney Books Company: Cincinnati, OH, USA, 2005; pp. 1–18.
2. Drummond, M. Pharmacoeconomics: Friend or foe? *Ann. Rheum. Dis.* **2006**, *65* (Suppl. 3), iii44–iii47. <https://doi.org/10.1136/ard.2006.058602>.
3. Nwokeji, E.; Rascati, K. Pharmacoeconomic Education in Colleges of Pharmacy Outside of the United States. *Am. J. Pharm. Educ.* **2005**, *69*, 348–355. <https://doi.org/10.5688/aj690352>.
4. Ofori-Asenso, R.; Brhlikova, P.; Pollock, A.M. Prescribing indicators at primary health care centers within the WHO African region: A systematic analysis (1995–2015). *BMC Public Health* **2016**, *16*, 724.
5. Cameron, A.; Ewen, M.; Ross-Degnan, D.; Ball, D.; Laing, R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. *Lancet* **2009**, *373*, 240–249.
6. Godman, B.; Hill, A.; Simoens, S.; Selke, G.; Selke Krulichova, I.; Zampiroli Dias, C.; Martin, A.P.; Oortwijn, W.; Timoney, A.; Gustafsson, L.L.; et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. *Expert. Rev. Pharm. Outcomes Res.* **2021**, *21*, 527–540.
7. Luzzatto, L.; Hyry, H.I.; Schieppati, A.; Costa, E.; Simoens, S.; Schaefer, F.; Roos, J.C.; Merlini, G.; Kääriäinen, H.; Garattini, S.; et al. Outrageous prices of orphan drugs: A call for collaboration. *Lancet* **2018**, *392*, 791–794.
8. Marselis, D.; Hordijk, L. From blockbuster to “nichebuster”: How a flawed legislation helped create a new profit model for the drug industry. *Bmj* **2020**, *370*, m2983.
9. Miot, J.; Thiede, M. Adapting Pharmacoeconomics to Shape Efficient Health Systems en route to UHC—Lessons from Two Continents. *Front. Pharmacol.* **2017**, *8*, 715. <https://doi.org/10.3389/fphar.2017.00715>.
10. Gavaza, P.; Rascati, K.; Oladapo, A.; Khoza, S. The State of Health Economic Research in South Africa. *Pharmacoeconomics* **2012**, *30*, 925–940. <https://doi.org/10.2165/11589450-000000000-00000>.
11. Al-Ziftawi, N.H.; Shafie, A.A.; Mohamed Ibrahim, M.I. Cost-effectiveness analyses of breast cancer medications use in developing countries: A systematic review. *Expert. Rev. Pharm. Outcomes Res.* **2021**, *21*, 655–666.
12. Erfani, P.; Bhangdia, K.; Stauber, C.; Mugunga, J.C.; Pace, L.E.; Fadelu, T. Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review. *Oncologist* **2021**, *26*, e1406–e1417.
13. Saokaew, S.; Rayanakorn, A.; Wu, D.B.; Chaikunapruk, N. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review. *Pharmacoeconomics* **2016**, *34*, 1211–1225.
14. Portnoy, A.; Jit, M.; Lauer, J.; Blommaert, A.; Ozawa, S.; Stack, M.; Murray, J.; Hutubessy, R. Estimating costs of care for meningitis infections in low- and middle-income countries. *Vaccine* **2015**, *33* (Suppl. 1), A240–A247.
15. Purkiss R. Pharmacoeconomics—the importance for pharmacists. *Hosp Pharm.* **2006**; *13*(2):34..
16. Catić, T.; Skrbo, S. Pharmacoeconomic Education for Pharmacy Students in Bosnia and Herzegovina. *Mater. Socio Med.* **2013**, *25*, 282–285. <https://doi.org/10.5455/msm.2013.25.282-285>.
17. Soliman, A.; Hussein, M.; Abdulhalim, A. Pharmacoeconomic Education in Egyptian Schools of Pharmacy. *Am. J. Pharm. Educ.* **2013**, *77*, 57. <https://doi.org/10.5688/ajpe77357>.
18. Rattinger, G.; Jain, R.; Ju, J.; Mullins, C. Principles of Economics Crucial to Pharmacy Students’ Understanding of the Prescription Drug Market. *Am. J. Pharm. Educ.* **2008**, *72*, 61–65. <https://doi.org/10.5688/aj720361>.
19. Reddy, M.; Rascati, K.; Wahawisan, J.; Rascati, M. Pharmacoeconomic Education in US Colleges and Schools of Pharmacy: An Update. *Am. J. Pharm. Educ.* **2008**, *72*, 51. <https://doi.org/10.5688/aj720351>.
20. Thomas, D.; Sam Sundararaj, K.; Shirwaikar, A.; Tarn, Y. Inclusion of Pharmacoeconomics course in the Undergraduate Pharmacy Education: A Global Trend Review. *Indian J. Pharm. Pract.* **2016**, *9*, 147–151. <https://doi.org/10.5530/ijopp.9.3.3>.
21. Bosmans, S.; Kairuz, T. Undergraduate pharmacy education in two countries in the southern hemisphere. *Pharm. Educ.* **2009**, *9*, 44–49.
22. Carapinha, J.L. A comparative review of the pharmacoeconomic guidelines in South Africa. *J. Med. Econ.* **2017**, *20*, 37–44.
23. South African National Department of Health (NDoH). Medicines and Related Substances Act (101 of 1965): Regulations relating to a transparent pricing system for Medicines and Scheduled Substances: Publication of the guidelines for pharmacoeconomic submissions. 2013. Available at: [http://www.medisacor.net/docs/GG/Medicines%20and%20related%20Substances%20Act%20101-1965%20%20Regulations%20relating%20to%20a%20transparent%20\(20130201-GGR-36118-00068\).pdf](http://www.medisacor.net/docs/GG/Medicines%20and%20related%20Substances%20Act%20101-1965%20%20Regulations%20relating%20to%20a%20transparent%20(20130201-GGR-36118-00068).pdf) (accessed on 24 August 2022).
24. South African National Department of Health (NDoH). National Drug Policy for South Africa. 1996. Available at: https://www.gov.za/sites/default/files/gcis_document/201409/drugpol0.pdf (accessed on 8 February 2018).
25. South African National Department of Health (NDoH). *National Health Act, 2003: National Health Insurance Policy: Towards Universal Health Coverage*; Government Gazette, The Government Printer: Pretoria, South Africa, 2017; Volume 624.
26. Meyer, J.C.; Schellack, N.; Stokes, J.; Lancaster, R.; Zeeman, H.; Defty, D.; Godman, B.; Steel, G. Ongoing Initiatives to Improve the Quality and Efficiency of Medicine Use within the Public Healthcare System in South Africa; A Preliminary Study. *Front. Pharmacol.* **2017**, *8*, 751.
27. Human, A. A Tale of Two Tiers: Inequality in South Africa’s Health Care System. *UBCMJ* **2009**, *1*, 33.
28. Godman B, Leong T, Abubakar AR, Kurdi A, Kalemeera F, Rwegerera GM; et al. Availability and Use of Long-Acting Insulin Analogues Including Their Biosimilars across Africa: Findings and Implications. *Intern. Med.* **2021**, *11*, 1–17.

29. Edoka, I.; Kohli-Lynch, C.; Fraser, H.; Hofman, K.; Tempia, S.; McMorro, M.; Ramkrishna, W.; Lambach, P.; Hutubessy, R.; Cohen, C. A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme. *Vaccine* **2021**, *39*, 412–422.
30. Fraser, H.; Tombe-Mdewa, W.; Kohli-Lynch, C.; Hofman, K.; Tempia, S.; McMorro, M.; Lambach, P.; Ramkrishna, W.; Cohen, C.; Hutubessy, R.; et al. Costs of seasonal influenza vaccination in South Africa. *Influ. Other Respir. Viruses* **2022**, *16*, 873–880.
31. Jamieson, L.; Johnson, L.F.; Matsimela, K.; Sande, L.A.; d'Elbée, M.; Majam, M.; Johnson, C.; Chidarikire, T.; Hatzold, K.; Terris-Prestholt, F.; et al. The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa: A model analysis. *BMJ Glob. Health* **2021**, *6* (Suppl. 4), e005598.
32. Campos, N.G.; Lince-Deroche, N.; Chibwasha, C.J.; Firnhaber, C.; Smith, J.S.; Michelow, P.; Meyer-Rath, G.; Jamieson, L.; Jordaan, S.; Sharma, M.; et al. Cost-Effectiveness of Cervical Cancer Screening in Women Living With HIV in South Africa: A Mathematical Modeling Study. *J. Acquir. Immune. Defic. Syndr.* **2018**, *79*, 195–205.
33. Pumpalova, Y.; Rogers, A.M.; Tan, S.X.; Herbst, C.L.; Ruff, P.; Neugut, A.I.; Hur, C. Modeling the Cost-Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer in South African Public Hospitals. *JCO Glob. Oncol.* **2021**, *7*, 1730–1741.
34. Alshreef, A.; MacQuilkan, K.; Dawkins, B.; Riddin, J.; Ward, S.; Meads, D.; Taylor, M.; Dixon, S.; Culyer, A.J.; Ruiz, F.; et al. Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa. *Value Health Reg Issues* **2019**, *19*, 65–74.
35. Michaeli, D.T.; Stoycheva, S.; Marcus, S.M.; Zhang, W.; Michaeli, J.C.; Michaeli, T. Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa. *Clin. Drug Investig.* **2022**, *42*, 333–343.
36. Saxena, A.; Stacey, N.; Puech, P.D.R.; Mudara, C.; Hofman, K.; Verguet, S. The distributional impact of taxing sugar-sweetened beverages: Findings from an extended cost-effectiveness analysis in South Africa. *BMJ Glob. Health* **2019**, *4*, e001317.
37. Erzse, A.; Stacey, N.; Chola, L.; Tugendhaft, A.; Freeman, M.; Hofman, K. The direct medical cost of type 2 diabetes mellitus in South Africa: A cost of illness study. *Glob. Health Action* **2019**, *12*, 1636611.
38. Marsh, S.E.; Truter, I. The South African Guidelines for Pharmacoeconomic Submissions' Evidence Requirements Compared with Other African Countries and The National Institute for Health and Care Excellence in England. *Expert Rev. Pharm. Outcomes Res.* **2020**, *20*, 155–168.
39. Mfizi E, Niragire F, Bizimana T, Mukanyangezi MF. Analysis of pharmaceutical inventory management based on ABC-VEN analysis in Rwanda: a case study of Nyamagabe district. *J Pharm Policy Pract.* 2023;16(1):30.
40. Kivoto, P.M.; Mulaku, M.; Ouma, C.; Ferrario, A.; Kurdi, A.; Godman, B.; Oluca, M. Clinical and Financial Implications of Medicine Consumption Patterns at a Leading Referral Hospital in Kenya to Guide Future Planning of Care. *Front. Pharmacol.* **2018**, *9*, 1348.
41. Gebretekle, G.B.; Mariam, D.H.; Mac, S.; Abebe, W.; Alemayehu, T.; Degu, W.A.; Libman, M.; Yansouni, C.P.; Fenta, T.G.; Semret, M.; et al. Cost-utility analysis of antimicrobial stewardship programme at a tertiary teaching hospital in Ethiopia. *BMJ Open* **2021**, *11*, e047515.
42. South African Qualifications Authority (SAQA). Registered Qualification: Bachelor of Pharmacy (Qualification ID: 72784). 2018. Available at: <http://regqs.saqa.org.za/viewQualification.php?id=72784> (accessed on 24 August 2022).
43. Modiba, W. *Pharmacoeconomics in the Healthcare System in Gauteng*; Tshwane University of Technology (TUT): Pretoria, South Africa, 2005.
44. Jayasree, D.; Uppu, B.; Devi, B. A study on awareness of pharmacoeconomics among postgraduates in a tertiary care teaching hospital. *Int. J. Res. Med. Sci.* **2016**, 1597–1603. <https://doi.org/10.18203/2320-6012.ijrms20161233>.
45. Tahashildar, Jarinabanu, Karunakar Kota, K. S. Kumar, Jameela Tahashildar, Lipa Mohanty, and Syed Yaseen Ahmed. "Assessment of the Knowledge and Perceptions about Pharmacoeconomics among Medical postgraduate students and Healthcare professionals at a Tertiary care teaching hospital, Udaipur, India." *Int J Curr. Res. Acad. Rev* 3, no. 2 (2015): 135-42..
46. Tabassum, R.; Hussain, S.; Banday, M. Evaluation of pharmacoeconomics awareness and its application among postgraduates of a tertiary care hospital: A cross-sectional observational study. *Asian J. Pharm. Clin. Res.* **2016**, *9*, 145–147.
47. Savkar M, Bhat N, Deepika G, Shwetha. Evaluation of pharmacoeconomics awareness among postgraduates: A questionnaire-based study. *Indian J. Basic Appl. Med. Res.* **2014**, *3*, 135–141.
48. Umair Khan, M.; Ahmad, A.; Hussain, K.; Salam, A.; Hasnain, Z.; Patel, I. The need for redesigned pharmacy practice courses in Pakistan: The perspectives of senior pharmacy students. *J. Educ. Eval. Health Prof.* **2015**, *12*, 27. <https://doi.org/10.3352/jeehp.2015.12.27>.
49. Armstrong, E.; Akaho, E.; Fujii, M.; Hosono, K. Evaluation of Teaching Pharmacoeconomics to Japanese Students. *J. Pharm. Teach.* **1996**, *5*, 67–85. https://doi.org/10.1300/j060v05n03_06.
50. Marinova, T.; Rascati, K. Pharmacoeconomics Education in US Colleges and Schools of Pharmacy. *Am. J. Pharm. Educ.* **2005**, *77*, 145. <https://doi.org/10.5688/ajpe777145>.
51. Rascati, K.; Conner, T.; Draugalis, J. Pharmacoeconomic Education in US Colleges and Schools of Pharmacy. *Am. J. Pharm. Educ.* **1998**, *62*, 167–169.
52. Garcia, M.M.; Barbosa, M.M.; Silva, R.M.; A Reis, E.; Alvares, J.; Acurcio, F.D.A.; Godman, B.; Junior, A.A.G. Indicator of access to medicines in relation to the multiple dimensions of access. *J. Comp. Eff. Res.* **2019**, *8*, 1027–1041.
53. Al Zahrani, E.M.; Al Naam, Y.A.; AlRabeeah, S.M.; Aldossary, D.N.; Al-Jamea, L.H.; Woodman, A.; Shawaheen, M.; Altit, O.; Quiambao, J.V.; Arulanantham, Z.J.; et al. E-Learning experience of the medical profession's college students during COVID-19 pandemic in Saudi Arabia. *BMC Med. Educ.* **2021**, *21*, 443.

54. Gupta, M.K.; Vohra, C.; Raghav, P. Assessment of knowledge, attitudes, and practices about antibiotic resistance among medical students in India. *J. Fam. Med. Prim. Care* **2019**, *8*, 2864–2869.
55. Burger, M.; Fourie, J.; Loots, D.; Mnisi, T.; Schellack, N.; Bezuidenhout, S.; Meyer, J. Knowledge and perceptions of antimicrobial stewardship concepts among final year pharmacy students in pharmacy schools across South Africa. *South Afr. J. Infect. Dis.* **2016**, *31*, 84–90. <https://doi.org/10.1080/23120053.2016.1192808>. Available at: <http://www.tandfonline.com/loi/ojid20> [Accessed: 21 March 2019].
56. Fosnacht, K.; Sarraf, S.; Howe, E.; Peck, L. How Important are High Response Rates for College Surveys? *Rev. High. Educ.* **2017**, *40*, 245–265. <https://doi.org/10.1353/rhe.2017.0003>.
57. Akazawa, M.; Yanagi, N. Pharmacoeconomics Education in Schools of Pharmacy in Japan: A Questionnaire Survey. *Value Health* **2018**, *21*, S55.
58. Freitas, G.; Balbinotto, G. Pharmacoeconomic Education in Brazilian Schools of Pharmacy. *Value Health* **2014**, *17*, A436. <https://doi.org/10.1016/j.jval.2014.08.1126>.
59. Jana, S.; Mondal, P. Pharmacoeconomics: The need to sensitize undergraduate medical students. *Indian J. Pharmacol.* **2005**, *37*, 277. <https://doi.org/10.4103/0253-7613.16849>.
60. Makhinova, T.; Makhinova, E.; Rascati, K. PHP146 Pharmacoeconomic Education for Pharmacy Students in the Russian Federation. *Value Health* **2012**, *15*, A314–A315.
61. Scott, D.; Pedersen, C. An Outcomes Research (Pharmacoeconomics/Pharmacoepidemiology) Course for PharmD Students. *Am. J. Pharm. Educ.* **2000**, *64*, 114–120.
62. Faleiros, D.R.; Nunes da Silva, E.; Santos, A.C.; Godman, B.B.; Goncalves Pereira, R.; Guerra Junior, A.A. Adoption of new therapies in the treatment of Hepatitis: A verification of the accuracy of budget impact analysis to guide investment decisions. *Expert Rev. Pharm. Outcomes Res.* **2022**, *22*, 927–939.
63. Faleiros DR, Álvares J, Almeida AM, de Araújo VE, Andrade EI, Godman BB; et al. Budget impact analysis of medicines: Updated systematic review and implications. *Expert. Rev. Pharm. Outcomes Res.* **2016**, *16*, 257–266.
64. Catharina de Beer, J.; Snyman, J.; Ker, J.; Miller-Janson, H.; Stander, M. Budget Impact Analysis of Empagliflozin in the Treatment of Patients With Type 2 Diabetes With Established Cardiovascular Disease in South Africa. *Value Health Reg. Issues* **2022**, *33*, 91–98.
65. Elsis, G.H.; Anwar, M.M.; Khattab, M.; Elebrashy, I.; Wafa, A.; Elhadad, H.; Awad, M.; Carapinha, J.L. Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt. *J. Med. Econ.* **2020**, *23*, 908–914.
66. Dalton, K.; Byrne, S. Role of the pharmacist in reducing healthcare costs: Current insights. *Integr. Pharm. Res. Pract.* **2017**, *6*, 37–46. <https://doi.org/10.2147/iprp.s108047>.
67. Mori, A.; Gavaza, P.; Robberstad, B. Role of pharmacoeconomics in developing countries. *Farmeconomia* **2013**, *14*, 3–5 <https://doi.org/10.7175/fe.v14i.638>.
68. Modisakeng, C.; Matlala, M.; Godman, B.; Meyer, J.C. Medicine shortages and challenges with the procurement process among public sector hospitals in South Africa; findings and implications. *BMC Health Serv. Res.* **2020**, *20*, 234.
69. Chigome, A.K.; Matlala, M.; Godman, B.; Meyer, J.C. Availability and Use of Therapeutic Interchange Policies in Managing Antimicrobial Shortages among South African Public Sector Hospitals; Findings and Implications. *Antibiotics* **2019**, *9*, 4.
70. Groenewald, Y. South Africa last in healthcare efficiency study. Fin24. 2017. Available at: <https://m.fin24.com/Economy/south-africa-last-in-healthcare-efficiency-study-20170609> (accessed on 9 January 2021).
71. Nasser, S.; Saad, A.; Karaoui, L. Mapping of the biomedical literature evaluation competencies based on pharmacy students' feedback. *Bio. Med. Cent. Med. Educ.* **2016**, *16*. <https://doi.org/10.1186/s12909-016-0583-7>.
72. Kolassa, E. A Basic Course in Pharmaceutical Economics. *J. Pharm. Teach.* **1994**, *4*, 15–27. https://doi.org/10.1300/j060v04n03_03.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.